אודות פרק זה
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
אנגלית
ארצות הברית
חיפוש פרקים ישנים
חפש פרקים קודמים של FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
פרקים אחרים בפודקאסט הזה
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
הצהרה: הפודקאסט והגרפיקה המוטבעים בדף זה הם מ-U.S. Food and Drug Administration, Center for Drug Evaluation and Research, שהוא רכושו של בעליו ואינו קשור או מאושר על ידי Listen Notes, Inc.
